A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects. December 11, 2014
Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s November 17, 2014
Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference November 10, 2014
Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease November 3, 2014
Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market October 27, 2014
Anavex Supports Alzheimer’s Foundation of America’s 3rd Annual Concepts in Care Educational Conference September 8, 2014
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer’s Clinical Trial August 26, 2014
Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor August 19, 2014
